Ann CHEN,Kuo-Feng HUA,Shuk-Man KA,Kuo-Ping CHAO,Wen-Liang CHANG,Kuo-Yuan HWA
申请号：
US14251426
公开号：
US20140343167A1
申请日:
2014.04.11
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.
